View Author
patient tumor treatment therapy somatostatin study neuroendocrine carcinoid liver disease metastase receptor department tumours liver metastases response surgery neuroendocrine tumors imaging survival cancer 177 lu-octreotate metastatic peptide analogue pancreatic university effect month syndrome result radionuclide lu-octreotate resection hospital carcinoma tumour uptake analog lesion diagnosis oncol octreotide medicine follow-up lu-dota group cycle trial consensus bone marrow combination carcinoid tumors marrow jensen rt gastroenterology somatostatin receptor scintigraphy phase neuroendocrinology table consensus statement kwekkeboom scintigraphy toxicity bakker wh grade radiolabeled somatostatin analogues symptom germany chemotherapy gastrinoma krenning ep y-dotatoc zollinger-ellison syndrome gepnet side effects jong m kidney statement
10 Most Recent Publications
|
Peptide receptor radionuclide therapy (PRRT) for GEP-NETs
(Article)
Bergsma, H. Vliet, E.I. van Teunissen, J.J.M. Kam, B.L. Herder, W.W. de Peeters, R.P. Krenning, E.P. Kwekkeboom, D. |
2012-12-01
|
|
Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
(Article)
Oberg, K. Knigge, U.P. Kwekkeboom, D. Perren, A. |
2012-10-01
|
|
Tumor response assessment to treatment with [
177Lu-DOTA
0,Tyr
3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors: Differential response of bone versus soft-tissue lesions
(Article)
Vliet, E.I. van Hermans, J.J. Ridder, M.A.J. de Teunissen, J.J.M. Kam, B.L. Krijger, R.R. de Krenning, E.P. Kwekkeboom, D. |
2012-09-01
|
|
Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy
(Article)
Vliet, E.I. van Teunissen, J.J.M. Kam, B.L. Jong, M. de Krenning, E.P. Kwekkeboom, D. |
2012-01-10
|
|
Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy
(Article)
Öberg, K. Reubi, J. Kwekkeboom, D. Krenning, E.P. |
2010-09-01
|
|
ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors
(Article)
Kianmanesh, R. Ruszniewski, P. Lesurtel, M. Chen, Y.J. Eriksson, B. Cioppi, F. O'Toole, D. Rindi, G. Kwekkeboom, D. Pape, U.F. Kulke, M. Sevilla Garcia, I. Scoazec, J.Y. Nilsson, O. Fazio, N. |
2010-06-01
|
|
Preclinical and Clinical Studies of Peptide Receptor Radionuclide Therapy
(Article)
Pool, S.E. Krenning, E.P. Koning, G.A. Eijck, C.H.J. van Teunissen, J.J.M. Kam, B.L. Valkema, R. Kwekkeboom, D. Jong, M. de |
2010-05-01
|
|
Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
(Article)
Kwekkeboom, D. Herder, W.W. de Eijck, C.H.J. van Kam, B.L. Essen, M. van Teunissen, J.J.M. Krenning, E.P. |
2010-03-01
|
|
Salvage therapy with177Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors
(Article)
Essen, M. van Krenning, E.P. Kam, B.L. Herder, W.W. de Feelders, R.A. Kwekkeboom, D. |
2010-03-01
|
|
Bone marrow dosimetry in peptide receptor radionuclide therapy with [ 177Lu-DOTA0,Tyr3]octreotate
(Article)
Forrer, F. Krenning, E.P. Kwekkeboom, D. Kooij, P.P.M. Bernard, B.F. Konijnenberg, M. Bakker, W.H. Teunissen, J.J.M. Jong, M. de Lom, K. van Herder, W.W. de |
2009-07-01
|
